Sunshine Biopharma Inc. (SBFM) News
Filter SBFM News Items
SBFM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SBFM News From Around the Web
Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.
Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. |
It's Down 26% But Sunshine Biopharma, Inc. (NASDAQ:SBFM) Could Be Riskier Than It LooksTo the annoyance of some shareholders, Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) shares are down a considerable 26% in... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we check out the shares worth watching on Tuesday! |
When Will Sunshine Biopharma, Inc. (NASDAQ:SBFM) Breakeven?With the business potentially at an important milestone, we thought we'd take a closer look at Sunshine Biopharma... |
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the |
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM). |
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expens |
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketMONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Com |
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc. |
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateMONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights. Full Year 2022 and Recent Highlights: Listing on NASDAQ.Bolstered balance sheet with cash and cash and cash equivalents of $21 million.Acquisition of Nora Phar |